European Commission Approves RINVOQ® (upadacitinib) for Non-Segmental Vitiligo in Adults and Adolescents

AbbVie has announced that the European Commission (EC) has approved RINVOQ (upadacitinib; 15 mg, once daily) for the treatment of adult and adolescent patients aged 12 years and older with non-segmental vitiligo (NSV) who are candidates for systemic therapy. This makes RINVOQ the first and only systemic medication approved in the European Union for NSV, the most common form of vitiligo.